Hallucinations during voriconazole therapy

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages

  Zonios, Dimitrios I ^a   Gea Banacloche, Juan ^b   Childs, Richard ^c   Bennett, John E ^a,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUDITORY HALLUCINATION; BLURRED VISION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOM; VISUAL HALLUCINATION; CHEMICALLY INDUCED DISORDER; HALLUCINATION; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 46249105803     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588844     Document Type: Article

References (12)

1. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
3. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1435-42.
4. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
5. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
6. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
7. Eiden C, Peyriere H, Cociglio M, et al; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41:755-63.
8. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136:739-42.
9. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39:1241-4.
10. Agrawal AK, Sherman LK. Voriconazole-induced musical hallucinations. Infection 2004; 32:293-5.
11. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47:2348-50.
12. Pfizer Global Research & Development. Background document for the Antiviral Drug Products Advisory Committee Meeting, October 4, 2001 (voriconazole tablets) (voriconazole injection). Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.pdf. Accessed 2 January 2008.